Patient

The drug industry’s self-regulatory body criticised Theramex for ‘alarming’ compliance issuesOne of the biggest producers of hormone replacement therapy has been censured by regulators for “systemic failures” that put patient safety in jeopardy.Theramex, the UK producer of HRT drugs Evorel and Intrarosa was found to have breached fundamental compliance standards including not updating crucial prescribing information – in some cases for several years – and not making it clear that a drug must not be used during pregnancy. Continue reading...

• Elijah Dottery, diagnosed with sickle cell anemia as a baby, became the first U-M patient to receive the newly FDA-approved stem cell therapy. • The treatment uses patient's own stem cells edited via CRISPR to produce functional hemoglobin, administered at Michigan Medicine. • This breakthrough matters for over 100,000 U.S. sickle cell patients, offering potential cure where prior therapies only managed symptoms.

• Thomas Jefferson University launched a multicenter clinical trial led by Manisha Verma, MD, and Victor Navarro, MD, at Jefferson Einstein Philadelphia Hospital to improve palliative care for advanced liver disease patients. • Advanced liver disease causes significant scarring and loss of function, leading to serious health challenges with limited quality-of-life support. • Funded by the Patient-Centered Outcomes Research Institute and published in JAMA Internal Medicine, the trial addresses a major care gap for ALD patients nationwide.

Exclusive: Pre-chemotherapy tests previously did not look for gene variant that put some ethnicities at higher risk of serious side effectsThousands of cancer patients from minority ethnic backgrounds will have access to “groundbreaking” genetic testing on the NHS that previously discriminated against them.This routine form of genetic testing, used before chemotherapy treatment, could save the lives of Black and minority ethnic cancer patients who already face poorer health outcomes after diagnosis compared with their white counterparts. Continue reading...

PhenMap tool could spare thousands of patients from treatment that would be ineffective for themA new AI-driven way of identifying how patients with advanced bowel cancer will respond to a drug that was recently introduced by the NHS has been announced.Researchers at London’s Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have developed the method with the goal of sparing potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. Continue reading...

• Eisai and Biogen announced positive top-line results from CLARITY AD trial extension on April 7, 2026, with lecanemab reducing cognitive decline by 27% over 18 months in 1,795 US patients. • Drug cleared 59% more amyloid plaques vs. placebo, with ARIA side effects in 12.6% of participants; full data at June AD/PD conference. • Approval could expand to mild cases, addressing 6.7 million US Alzheimer's sufferers; analysts predict $2.4 billion annual sales.

People encouraged to ‘come forward as normal’ when BMA members begin industrial action over pay on TuesdayThe NHS is urging patients not to put off seeking the care they need when resident doctors press ahead with strike action from Tuesday, a stoppage that the health secretary has called “disappointing”.Tens of thousands of resident doctors in England are to stage a six-day strike after the government took a key part of its offer off the table. Continue reading...

• A Philadelphia cancer patient who had exhausted conventional treatment options was kept alive using a novel T-cell therapy developed and administered at Rutgers Health. • The case represents a breakthrough application of immunotherapy, offering hope to patients facing terminal cancer diagnoses with limited options. • The success demonstrates the therapeutic potential of advanced cellular therapies and highlights Rutgers Health's role in pioneering cutting-edge cancer treatment innovations.

People receive rehab only three to four days a week in hospital – and one to two days once they are discharged, data suggestsThe NHS is failing stroke patients and limiting their chances of recovery because of a shortage of rehabilitation care staff, health leaders have said.More people are surviving strokes than ever before in the UK. But their hopes of getting better are being dashed because of a lack of physiotherapists and other specialist staff, according to the Chartered Society of Physiotherapy and the Association of Chartered Physiotherapists in Neurology. Continue reading...

• The SPIRIT-HF study, presented at ACC.26 in New Orleans (March 28-30, 2026), found that spironolactone increased hospitalizations and serious adverse events in patients with HFpEF (heart failure with preserved ejection fraction) or HFmrEF (mildly reduced ejection fraction). • Results raise significant safety questions about the drug's efficacy in these patient populations, potentially challenging current treatment protocols. • The findings were presented to cardiologists and cardiovascular specialists at the American College of Cardiology's annual conference, the largest gathering of heart disease specialists.

Patients experiencing raised bedside rails, doors and pathways blocked by furniture and physical interventionsPeople with dementia are being subjected to restraints and non-consensual sedation while in hospitals in England, according to the first study of its kind.These restrictive practices were found to be an “embedded aspect of routine ward care”, according to the analysis, with such examples including dementia patients having their bedside rails raised, doors and pathways blocked by furniture, experiencing verbal commands to sit down or go back to bed, and physical interventions such as non-consensual sedation. Continue reading...

CDC interim analysis from September 2025 to February 2026 shows this season's flu vaccine effectiveness at 22-34% against outpatient visits for adults and 30-41% for those 65+, with hospitalization protection at 30-31%, due to H3N2 strain mismatch. The season saw 27 million illnesses, 350,000 hospitalizations, and 22,000 deaths, lower than last year's peaks but with 101 child deaths, 85% unvaccinated. Despite flaws, experts like Dr. William Schaffner stress shots prevent severe outcomes, with adult rates at 46.5%. Vaccination campaigns will target improved strains for next season.

CDC studies from September 2025 to February 2026 estimate flu vaccine effectiveness (VE) at 22-34% against influenza A/B outpatient visits for adults and 30-41% for those 65+, with 30-31% against hospitalizations. Patrick Maloney, PhD, from CDC's National Center for Immunization and Respiratory Diseases, led the analysis. Low VE underscores need for improved formulations amid slumping protection. Findings inform next season's vaccine development.